109 related articles for article (PubMed ID: 25082363)
1. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?
Ebert MA; Bulsara M; Haworth A; Kearvell R; Richardson S; Kennedy A; Spry NA; Bydder SA; Joseph DJ; Denham JW
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):99-108. PubMed ID: 25082363
[TBL] [Abstract][Full Text] [Related]
2. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
[TBL] [Abstract][Full Text] [Related]
3. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.
Wills L; Maggs R; Lewis G; Jones G; Nixon L; Staffurth J; Crosby T;
Radiat Oncol; 2017 Nov; 12(1):179. PubMed ID: 29141663
[TBL] [Abstract][Full Text] [Related]
4. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial.
Marcello M; Ebert MA; Haworth A; Steigler A; Kennedy A; Bulsara M; Kearvell R; Joseph DJ; Denham JW
J Med Imaging Radiat Oncol; 2018 Apr; 62(2):248-255. PubMed ID: 29222833
[TBL] [Abstract][Full Text] [Related]
5. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT.
Valdagni R; Rancati T; Fiorino C; Fellin G; Magli A; Baccolini M; Bianchi C; Cagna E; Greco C; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Vavassori V
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1065-73. PubMed ID: 18234449
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy.
Trada Y; Kneebone A; Paneghel A; Pearse M; Sidhom M; Tang C; Wiltshire K; Haworth A; Fraser-Browne C; Martin J
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1045-51. PubMed ID: 26475066
[TBL] [Abstract][Full Text] [Related]
7. Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis.
Troeller A; Yan D; Marina O; Schulze D; Alber M; Parodi K; Belka C; Söhn M
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):435-43. PubMed ID: 25636766
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity.
Jani AB; Su A; Milano MT
Urology; 2006 Jan; 67(1):147-51. PubMed ID: 16413351
[TBL] [Abstract][Full Text] [Related]
9. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
10. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
Steigler A; Mameghan H; Lamb D; Joseph D; Matthews J; Franklin I; Turner S; Spry N; Poulsen M; North J; Kovacev O; Denham J
Australas Radiol; 2000 Feb; 44(1):65-71. PubMed ID: 10761262
[TBL] [Abstract][Full Text] [Related]
11. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
12. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
[TBL] [Abstract][Full Text] [Related]
13. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
[TBL] [Abstract][Full Text] [Related]
14. Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02).
Christie D; Le T; Watling K; Cornes D; O'Brien P; Hitchins R
J Med Imaging Radiat Oncol; 2009 Apr; 53(2):203-6. PubMed ID: 19527368
[TBL] [Abstract][Full Text] [Related]
15. Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.
Haworth A; Kearvell R; Greer PB; Hooton B; Denham JW; Lamb D; Duchesne G; Murray J; Joseph D
Radiother Oncol; 2009 Mar; 90(3):299-306. PubMed ID: 19017549
[TBL] [Abstract][Full Text] [Related]
16. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.
Matzinger O; Duclos F; van den Bergh A; Carrie C; Villà S; Kitsios P; Poortmans P; Sundar S; van der Steen-Banasik EM; Gulyban A; Collette L; Bolla M;
Eur J Cancer; 2009 Nov; 45(16):2825-34. PubMed ID: 19682889
[TBL] [Abstract][Full Text] [Related]
17. Late gastrointestinal and urogenital side-effects after radiotherapy--incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer.
Schmid MP; Pötter R; Bombosch V; Sljivic S; Kirisits C; Dörr W; Goldner G
Radiother Oncol; 2012 Jul; 104(1):114-8. PubMed ID: 22727264
[TBL] [Abstract][Full Text] [Related]
18. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
19. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
20. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm.
Baumert BG; Brada M; Bernier J; Kortmann RD; Dehing-Oberije C; Collette L; Davis JB
Radiother Oncol; 2008 Aug; 88(2):163-72. PubMed ID: 18455252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
